Documenting Re-Consent for Protocol Amendments

Published on 22/12/2025

How to Properly Document Re-Consent During Protocol Amendments

Table of Contents

Introduction to Re-Consent

Informed consent is not a one-time event. In clinical trials, whenever a protocol amendment introduces changes that impact participant rights, safety, or understanding of trial procedures, re-consent becomes a mandatory ethical and regulatory requirement. Re-consent ensures participants remain fully informed and that their agreement to continue participation reflects the most current trial information.

Examples of protocol amendments requiring re-consent include:

➤ Change in dosage regimen or study duration
➤ New safety findings or risks identified
➤ Alterations in eligibility criteria
➤ Modifications in study endpoints or procedures
➤ Updates in compensation policies

Regulatory Expectations for Re-Consent

ICH-GCP, FDA, and EMA clearly state that participants must be re-consented whenever a protocol change impacts their decision-making. IRBs and Ethics Committees review revised consent forms before implementation. Sponsors are responsible for providing clear guidance and documentation tools to ensure compliance.

Key regulatory requirements:

✅ FDA 21 CFR 50.25 mandates updated consent documents for new information on risks/benefits.
✅ EMA and EU CTR require version-controlled re-consent forms submitted to ethics committees.
✅ ICH-GCP 4.8.2 states informed consent should be revised whenever new information becomes available.

Step-by-Step Process for Documenting Re-Consent

A systematic approach ensures compliance and minimizes delays:

➤ Draft an amended

consent form in clear, layperson language.

➤ Submit revised documents to the IRB/IEC for approval.

➤ Train site staff on key changes before implementation.

➤ Present updated consent to participants, ensuring adequate discussion.

➤ Obtain signatures and date on the new version.

➤ File signed forms in both participant files and the Trial Master File (TMF).

Sample Documentation Table for Re-Consent

Element	Requirement	Compliance Marker
Version Control	Unique version/date on form	✅
Participant Signature	Updated consent signed	✅
Investigator Signature	Verification of discussion	✅
IRB/IEC Approval	Mandatory before implementation	✅
Archiving	Stored in TMF and participant file	✅

Case Study: Re-Consent in a Phase III Oncology Trial

In a Phase III oncology study, new safety data indicated higher risk of neutropenia. The sponsor amended the protocol and developed a revised consent form. After expedited IRB approval, re-consent was obtained from 95% of participants within 14 days. This transparent process prevented regulatory action and preserved participant trust. Without re-consent, the trial risked suspension and credibility damage.

Best Practices for Re-Consent

✅ Maintain a master log of re-consented participants with version details.
✅ Provide translated consent versions for non-English speakers.
✅ Use electronic re-consent systems with audit trails for efficiency.
✅ Allow sufficient time for participants to consider new information.
✅ Document re-consent discussions in source notes.

Conclusion

Documenting re-consent during protocol amendments is not only a regulatory requirement but also a demonstration of respect for participant autonomy. Proper documentation ensures transparency, protects participants, and maintains trial integrity. Sponsors and sites that adopt robust re-consent SOPs reduce compliance risks and strengthen relationships with regulatory authorities and participants alike.